Joe Papa

Jim Cramer announced his top stock picks for 2022 Wednesday on CNBC's "Fast Money Halftime Report." The former hedge fund manager put Eli Lilly And Co (NYSE: LLY) and Chevron Corp (NYSE: CVX) at the top of his list. "Everyone is pretty positive, that I talk to, about what's...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company.   But since bottoming at $8.31 per share this year, the company has made "great...

Analysts at Cantor Fitzgerald turned incrementally bullish on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the once-troubled pharmaceutical company is showing signs of sustaining momentum. Cantor Fitzgerald's Louise Chen maintains an Overweight rating on Valeant's stock with a price...

Bill Ackman's Pershing Square released an annual update presentation for investors and the public. One of Ackman's most notable holdings is Valeant Pharmaceuticals Intl Inc (NYSE: VRX), the troubled pharmaceutical company that was plagued with controversies and concerns over its debt...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) CEO Joseph Papa bought 202,000 shares at $24.48 per share Monday morning. The purchase came after key events last week. Tuesday: Reported Q1 Adj. EPS $1.27 vs $1.37 Est., Sales $2.4B vs $2.38B Est. Tuesday: Cut FY16 Sales Outlook from $11B-$11....

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has become one of the most talked about companies on Wall Street given its policy of drug pricing. Activist investor, major Valeant shareholder and board member was a guest on CNBC to discuss the companies past, present and future. Ackman was asked...

The next chapter in the Valeant Pharmaceuticals Intl Inc (NYSE: VRX) story began today when the company named Joseph Papa as its new CEO. Shareholders are hoping that Papa can right the ship after a whirlwind of controversy has driven Valeant’s share price down 63.1 percent so far in 2016...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) disclosed it elevated John Hendrickson as its CEO. The move comes after its CEO, Joseph Papa, resigned to join the troubled Valeant Pharmaceuticals Intl Inc (NYSE: VRX) as its Chairman and CEO. Papa is expected to join Valeant in early next month...

In a report published Wednesday, BMO Capital Markets analyst David Maris discussed key takeaways from a day of meetings with several specialty pharmaceutical companies. Below are some of the highlights of notable presentations. Allergan PLC (NYSE: AGN): The company is planning to work...